478264-00-5

Usage

Uses

Used in Pharmaceutical Industry:
6-Methylpyridine-3-sulfonyl chloride is used as a reagent in the synthesis of various pharmaceuticals. Its strong sulfonating and chlorinating abilities make it a useful intermediate for the production of active pharmaceutical ingredients.
Used in Agrochemical Industry:
In the agrochemical industry, 6-Methylpyridine-3-sulfonyl chloride is utilized as a building block in the synthesis of agrochemicals. Its properties contribute to the development of effective and targeted agrochemical products.
Used in Dye and Pigment Synthesis:
6-Methylpyridine-3-sulfonyl chloride is employed as a key intermediate in the synthesis of dyes and pigments. Its unique chemical structure allows for the creation of a wide range of colorants used in various applications.
Used in Organic Synthesis:
As a versatile chemical reagent, 6-Methylpyridine-3-sulfonyl chloride is widely used in organic synthesis for the preparation of various organic compounds. Its strong sulfonating and chlorinating abilities facilitate the formation of new chemical bonds and the synthesis of complex molecules.
Used in Fine Chemicals Production:
6-Methylpyridine-3-sulfonyl chloride is also utilized in the production of fine chemicals, which are high-purity chemicals used in various industries such as pharmaceuticals, fragrances, and flavors. Its unique properties make it an essential component in the synthesis of these high-value products.

Upstream product

• 3430-13-5 5-bromo-2-methylpyridine 
• 4808-69-9 6-methyl-3-sulfonylpyridine 
• 907202-06-6 5-(benzylthio)-2-methylpyridine 
• 80287-53-2 5-Amino-2-methylpyridine 

Downstream Products

• 1138034-14-6 sodium 6-methylpyridine-3-sulfinate 
• 478263-70-6 5-methoxy-2-(6-methylpyridine-3-sulfonylamino)-N-(1-phenylpropyl)-benzamide 

Relevant academic research and scientific papers

HEPATITIS B VIRAL ASSEMBLY EFFECTORS

Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.

Thermodynamic N-donor trans influence in labile pseudo-octahedral zinc complexes: A delusion?

While the forces responsible for the chelate effect are well-established in coordination chemistry, the origin and implementation of the related thermodynamic trans influence remains debatable. This work illustrates a simple approach for quantifying this effect in labile pseudo-octahedral [Zn(Lk)3]2+ complexes lacking stereochemical preferences (Lk = L1-L4 are unsymmetrical didentate α,α′-diimine ligands). In line with statistics, the triply degenerated meridional isomers mer-[Zn(Lk)3]2+ are stabilized by 0.8 ≥ ΔGexch mer→fac ≥ 4.2 kJ/mol over their nondegenerated facial analogues fac-[Zn(Lk)3]2+ and therefore display no apparent trans influence at room temperature. However, the dissection of the free energy terms into opposite enthalpic (favoring the facial isomers) and entropic (favoring the meridional isomers) contributions reveals a trans influence assigned to solvation processes occurring in polar solvents. Altogether, the thermodynamic trans influence operating in [Zn(α,α′-diimine)3]2+ complexes is 1-2 orders of magnitude smaller than the chelate effect. A weak templating effect provided by a noncovalent lanthanide tripod is thus large enough to produce the wanted facial isomer at room temperature.

5-Membered heterocyclic compound

The present invention provides 5-membered heterocycle compounds represented by the following general formula (I): The present compounds have a superior acid secretion inhibitory effect, and shows an antiulcer activity and the like.

Acid secretion inhibitor

The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity and the like. The present invention provides a compound represented by the formula (I) wherein R1 is a nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle, the nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle optionally has substituent(s), R2 is an optionally substituted C6-14 aryl group, an optionally substituted thienyl group or an optionally substituted pyridyl group, R3 and R4 are each a hydrogen atom, or one of R3 and R4 is a hydrogen atom and the other is an optionally substituted lower alkyl group, an acyl group, a halogen atom, a cyano group or a nitro group, and R5 is an alkyl group or a salt thereof.

PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS

The present invention is related to pyrazine derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.